| 1. |
- Martin-Bernabe, A, et al.
(författare)
-
Quantitative Proteomic Approach Reveals Altered Metabolic Pathways in Response to the Inhibition of Lysine Deacetylases in A549 Cells under Normoxia and Hypoxia
- 2021
-
Ingår i: International journal of molecular sciences. - : MDPI AG. - 1422-0067. ; 22:7
-
Tidskriftsartikel (refereegranskat)abstract
- Growing evidence is showing that acetylation plays an essential role in cancer, but studies on the impact of KDAC inhibition (KDACi) on the metabolic profile are still in their infancy. Here, we analyzed, by using an iTRAQ-based quantitative proteomics approach, the changes in the proteome of KRAS-mutated non-small cell lung cancer (NSCLC) A549 cells in response to trichostatin-A (TSA) and nicotinamide (NAM) under normoxia and hypoxia. Part of this response was further validated by molecular and biochemical analyses and correlated with the proliferation rates, apoptotic cell death, and activation of ROS scavenging mechanisms in opposition to the ROS production. Despite the differences among the KDAC inhibitors, up-regulation of glycolysis, TCA cycle, oxidative phosphorylation and fatty acid synthesis emerged as a common metabolic response underlying KDACi. We also observed that some of the KDACi effects at metabolic levels are enhanced under hypoxia. Furthermore, we used a drug repositioning machine learning approach to list candidate metabolic therapeutic agents for KRAS mutated NSCLC. Together, these results allow us to better understand the metabolic regulations underlying KDACi in NSCLC, taking into account the microenvironment of tumors related to hypoxia, and bring new insights for the future rational design of new therapies.
|
|
| 2. |
- Asah, Stanley T, et al.
(författare)
-
Value exclusion in social–scientific approaches for assessing and valuing ecosystem features: Implications for behavioral compliance
- 2023
-
Ingår i: BioScience. - 0006-3568. ; 73:9, s. 663-670
-
Tidskriftsartikel (refereegranskat)abstract
- Value inclusion is critical for effective ecosystem science policy and largely emerged from critiques of the value-exclusionary attributes of ecological and economic approaches to value assessments and valuations. But whether and how value is excluded during social–scientific approaches to the assessments and valuations of ecosystem features has not received adequate attention. We identify and discuss instances of when and how value is excluded during social–scientific approaches to the assessments and valuations of ecosystem features to which people ascribe value. We illustrate the implications of value exclusion on social compliance with ecosystem management and policy recommendations, a vital overlooked aspect of policy effectiveness. We also extend the meaning of value exclusion beyond value omission to include misidentification and misattribution of salience to valued ecosystem features. We offer suggestions for enabling value inclusion where ways to minimize exclusion are inapparent.
|
|
| 3. |
- Ashrafian, Hutan, et al.
(författare)
-
Metabolomics : The Stethoscope for the Twenty-First Century
- 2021
-
Ingår i: Medical principles and practice. - : S. Karger. - 1011-7571 .- 1423-0151. ; 30:4, s. 301-310
-
Tidskriftsartikel (refereegranskat)abstract
- Metabolomics encompasses the systematic identification and quantification of all metabolic products in the human body. This field could provide clinicians with novel sets of diagnostic biomarkers for disease states in addition to quantifying treatment response to medications at an individualized level. This literature review aims to highlight the technology underpinning metabolic profiling, identify potential applications of metabolomics in clinical practice, and discuss the translational challenges that the field faces. We searched PubMed, MEDLINE, and EMBASE for primary and secondary research articles regarding clinical applications of metabolomics. Metabolic profiling can be performed using mass spectrometry and nuclear magnetic resonance-based techniques using a variety of biological samples. This is carried out in vivo or in vitro following careful sample collection, preparation, and analysis. The potential clinical applications constitute disruptive innovations in their respective specialities, particularly oncology and metabolic medicine. Outstanding issues currently preventing widespread clinical use are scalability of data interpretation, standardization of sample handling practice, and e-infrastructure. Routine utilization of metabolomics at a patient and population level will constitute an integral part of future healthcare provision.
|
|
